Journal of Hepatology
Volume 51, Issue 4 , Pages 798-809 , October 2009

Transfusion-transmitted hepatitis B virus infection

  • Daniel Candotti

      Affiliations

    • National Health Service Blood & Transplant, Cambridge Blood Centre, Long Road, Cambridge CB2 2PT, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 1223 548138; fax: +44 1223 548155.
    • ,
  • Jean-Pierre Allain

      Affiliations

    • Department of Haematology, University of Cambridge, Cambridge, UK

References 

  1. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112–125
  2. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang. 2004;86:83–91
  3. Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion. 2008;48:1001–1026
  4. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion. 2003;43:788–798
  5. Scheiblauer H, Soboll H, Nick S. Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol. 2006;78:S66–S70
  6. Matsubara N, Kusano O, Sugamata Y, Itoh T, Mizuii M, Tanaka J, et al. A novel hepatitis B virus surface antigen immunoassay as sensitive as hepatitis B virus nucleic acid testing in detecting early infection. Transfusion. 2009;45:585–595
  7. Lien TX, Tien NT, Chanpong GF, Cuc CT, Yen VT, Soderquist R, et al. Evaluation of rapid diagnostic tests for the detection of human immunodeficiency virus types 1 and 2, hepatitis B surface antigen, and syphilis in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg. 2000;62:301–309
  8. Owusu-Ofori S, Temple J, Sarkodie F, Anokwa M, Candotti D, Allain JP. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion. 2005;45:133–140
  9. Randrianirina F, Carod JF, Ratsima E, Chrétien JB, Richard V, Talarmin A. Evaluation of the performance of four rapid tests for detection of hepatitis B surface antigen in Antananarivo, Madagascar. J Virol Methods. 2008;151:294–297
  10. Allain JP, Candotti D, Soldan K, Sarkodie F, Phelps B, Giachetti C, et al. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood. 2003;101:2419–2425
  11. Weber B, Dengler T, Berger A, Doerr HW, Rabenau H. Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: IMMULITE HBsAg and IMMULITE 2000 HBsAg. J Clin Microbiol. 2003;41:135–143
  12. Olinger CM, Weber B, Otegbayo JA, Ammerlaan W, van der Taelem-Brulé N, Muller CP. Hepatitis B virus genotype E surface antigen detection with different immunoassays and diagnostic impact of mutations in the preS/S gene. Med Microbiol Immunol. 2007;196:247–252
  13. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol. 2005;32:102–112
  14. Hsu H-Y, Chang M-H, Ni Y-H, Chen H-L. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut. 2004;53:1499–1503
  15. Theamboonlers A, Chongsrisawat V, Jantaradsamee P, Poovorawan Y. Variants within the “a” determinant of HBs gene in children and adolescents with and without hepatitis B vaccination as part of Thailand’s Expanded Program on Immunization (EPI). Tohoku J Exp Med. 2001;193:197–205
  16. Joller-Jemelka HI, Wicki AN, Grob PJ. Detection of HBs antigen in “anti-HBc alone” positive sera. J Hepatol. 1994;21:269–272
  17. Zhang JM, Xu Y, Wang XY, Yin YK, Wu XH, Weng XH, et al. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis. 2007;44:1161–1169
  18. Kiely P, Stewart Y, Castro L. Analysis of voluntary blood donors with biologic false reactivity on chemiluminescent immunoassays and implications for donor management. Transfusion. 2003;43:584–590
  19. Vermeulen M, Lelie N, Sykes W, Crookes R, Swanevelder J, Gaggia L, et al. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009 Feb 27. [Epub ahead of print].
  20. Dow BC, Yates P, Galea G, Munro H, Buchanan I, Ferguson K. Hepatitis B vaccines may be mistaken for confirmed hepatitis B surface antigen-positive blood donors. Vox Sang. 2002;82:15–17
  21. Davis AR, Brotchie HL, Mundkur BA, Ismary SL. Transient hepatitis B surface antigenemia in a blood donor after a combination hepatitis A and B vaccine. Transfusion. 2003;43:545
  22. Roth WK, Seifried E. The German experience with NAT. Trans Med. 2002;12:255–258
  23. Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, et al. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion. 2003;43:696–704
  24. Schifman RB, Rivers SL, Sampliner RE, Krammes JE. Significance of isolated hepatitis B core antibody in blood donors. Arch Intern Med. 1993;153:2261–2266
  25. Almeida Neto C, Strauss E, Sabino EC, Sucupira MC, Chamone DA. Significance of isolated hepatitis B core antibody in blood donors from São Paulo. Rev Inst Med Trop Sao Paulo. 2001;43:203–208
  26. Brojer E, Grabarczyk P, Liszewski G, Mikulska M, Allain JP, Letowska M, et al. Characterization of HBV DNA+/HBsAg− blood donors in Poland identified by triplex NAT. Hepatology. 2006;44:1666–1674
  27. Velati C, Romano L, Fomiatti L, Baruffi L, Zanetti AR SIMTI Research Group. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion. 2008;48:2205–2213
  28. Margaritis AR, Brown SM, Seed CR, Kiely P, D’Agostino B, Keller AJ. Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA. Transfusion. 2007;47:1783–1793
  29. Nantachit N, Thaikruea L, Thongsawat S, Leetrakool N, Fongsatikul L, Sompan P, et al. Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand. Transfusion. 2007;47:1803–1808
  30. Li L, Chen PJ, Chen MH, Chak KF, Lin KS, Lin Tsai SJ. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus. Transfusion. 2008;48:1198–1206
  31. Matsumoto C, Tadokoro K, Fujimura K, Hirakawa S, Mitsunaga S, Juji T. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion. 2001;41:878–884
  32. Sato S, Ohhashi W, Ihara H, Sakaya S, Kato T, Ikeda H. Comparison of the sensitivity of NAT using pooled donor samples for HBV and that of a serologic HBsAg assay. Transfusion. 2001;41:1107–1113
  33. Yotsuyanagi H, Yasuda K, Moriya K, Shintani Y, Fujie H, Tsutsumi T, et al. Frequent presence of HBV in the sera of HBsAg-negative, anti-HBc-positive blood donors. Transfusion. 2001;41:1093–1099
  34. Koppelman MHG, Sjerps MC, Reesink HW, Cuypers HTM. Evaluation of COBAS AmpliPrep nucleic acid extraction in conjunction with COBAS AmpliScreen HBV DNA, HCV RNA and HIV-1 RNA amplification and detection. Vox Sang. 2005;89:193–200
  35. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49:654–659
  36. Candotti D, Grabarczyk P, Ghiazza P, Roig R, Casamitjana N, Iudicone P, et al. Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol. 2008;49:537–547
  37. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology. 2000;31:488–495
  38. Hass M, Hannoun C, Kalinina T, Sommer G, Manegold C, Gunther S. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology. 2005;42:93–103
  39. Baginski I, Chemin I, Hantz O, Pichoud C, Jullien AM, Chevre JC, et al. Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of posttransfusion hepatitis. Transfusion. 1992;32:215–220
  40. Manzini P, Abate ML, Valpreda C, Milanesi P, Curti F, Rizzetto M, et al. Evidence of acute primary occult hepatitis B virus infection in an Italian repeat blood donor. Transfusion. 2009;49:757–764
  41. Yoshikawa A, Gotanda Y, Minegishi K, Taira R, Hino S, Tadokoro K, et al. Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage. Transfusion. 2007;47:1162–1171
  42. Dow BC, Peterkin MA, Green RHA, Cameron SO. Hepatitis B virus transmission by blood donation negative for hepatitis B surface antigen, antibody to HBsAg, antibody to hepatitis B core antigen and HBV DNA. Vox Sang. 2001;81:140
  43. Busch MP. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?. Trans Clin Biol. 2004;11:26–32
  44. Yugi H, Mizui M, Tanaka J, Yoshizawa H. Hepatitis B virus (HBV) screening strategy to ensure the safety of blood for transfusion through a combination of immunological testing and nucleic acid amplification testing – Japanese experience. J Clin Virol. 2006;36:S56–S64
  45. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion. 2003;43:721–729
  46. Busch M, Walderhaug M, Custer B, Allain JP, Reddy R, McDonough B. Risk assessment and cost-effectiveness/utility analysis. Biologicals. 2009;37:78–87
  47. Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion. 2004;44:1332–1339
  48. Nardone A, Anastassopoulou CG, Theeten H, Kriz B, Davidkin I, Thierfelder W, et al. A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiol Infect. 2008;23:1–9
  49. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology. 2007;132:1287–1293
  50. Chang MW. Impact of hepatitis B vaccination on hepatitis B disease and nucleic acid testing in high-prevalence populations. J Clin Virol. 2006;36:S45–S50
  51. Pereira JSF, Goncales NSL, Silva C, Lazarini MSK, Pavan MHP, Fais VC, et al. HBV vaccination of HCV-infected patients with occult HBV infection and anti-HBc-positive blood donors. Braz J Med Biol Res. 2006;39:525–531
  52. Singh H, Pradhan M, Singh RL, Phadke S, Naik SR, Aggarwal R, et al. High frequency of hepatitis B virus infection in patients with β-thalassemia receiving multiple transfusions. Vox Sang. 2003;84:292–299
  53. Coste J, Reesink HW, Engelfriet CP, Laperche S, Brown S, Busch MP, et al. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang. 2005;88:289–303
  54. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol. 2006;36:S23–S29
  55. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion. 2005;45:254–264
  56. Van der Bij AK, Coutinho RA, van der Poel CL. Surveillance of risk profiles among new and repeat blood donors with transfusion-transmissible infections from 1995 through 2003 in the Netherlands. Transfusion. 2006;46:1729–1736
  57. Korelitz JJ, Busch MP, Kleinman SH, Williams AE, Gilcher RO, Ownby HE, et al. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. Transfusion. 1997;37:634–640
  58. Janssen MP, Cator EA, van der Poel CL, Schaasberg WP, Bonsel GJ, van Hout BA. Monitoring viral incidence rates: tools for the implementation of European Union regulations. Vox Sang. 2009;96:298–308
  59. Soldan K, Davison K, Dow B. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003.. Euro Surveill. 2005;10:17–19
  60. Laperche S, Maniez M, Barlet V, El Ghouzzi M-H, Le Vacon F, Levayer T, et al. A revised method for estimating hepatitis B virus transfusion residual risk based on antibody to hepatitis B core antigen incident cases. Transfusion. 2008;48:2308–2314
  61. Offergeld R, Faensen D, Ritter S, Hamouda O. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000–2002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill. 2005;10:8–11
  62. Niederhauser C, Schneider P, Fopp M, Ruefer A, Levy G. Incidence of viral markers and evaluation of the estimated risk in the Swiss blood donor population from 1996 to 2003. Euro Surveill. 2005;10:14–16
  63. O’Brien S, Yi Q-L, Fan W, Scalia V, Kleinman SH, Vamvakas EC. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion. 2007;47:316–325
  64. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975–979
  65. Kleinman SH, Strong DM, Tegtmeier GGE, Holland PV, Gorlin JB, Cousins CR, et al. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion. 2005;45:1247–1257
  66. Seed CR, Kiely P, Keller AJ. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus. Intern Med J. 2005;35:592–598
  67. Tosti ME, Solinas S, Prati D, Salvaneschi L, Manca M, Francesconi M, et al. An estimate of the current risk of transmitting blood–borne infections through blood transfusion in Italy. Br J Haematol. 2002;117:215–219
  68. Alvarez do Barrio M, Gonzalez Diez R, Hernandez Sanchez JM, Oyonarte Gomez S. Residual risk of transfusion-transmitted viral infections in Spain, 1997–2002, and impact of nucleic acid testing. Euro Surveill. 2005;10:20–22
  69. Shang G, Seed CR, Wang F, Nie D, Farrugia A. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. Transfusion. 2007;47:529–539
  70. Allain JP. Estimation of HBV transfusion risk. Transfusion. 2009;49:1019–1021
  71. Schmidt M, Nubling CM, Scheiblauer H, Chudy M, Walch LA, Seifried E, et al. Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests. Vox Sang. 2006;91:237–243
  72. Hennig H, Puchta I, Luhm J, Schlenke P, Goerg S, Kirchner H. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood. 2002;100:2637–2641
  73. Vitale F, Tramuto F, Orlando A, Vizzini G, Meli V, Cerame G, et al. Can the serological status of anti-HBc alone be considered a sentinel marker for detection of occult HBV infection?. J Med Virol. 2008;80:577–582
  74. Chevrier MC, St-Louis M, Perreault J, Caron B, Castilloux C, Laroche J, et al. Detection and characterization of hepatitis B virus of anti-hepatitis B core antigen-reactive blood donors in Quebec with an in-house nucleic acid testing assay. Transfusion. 2007;47:1794–1802
  75. O’Brien SF, Fearon MA, Yi Q-L, Fan W, Scalia V, Muntz IR, et al. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion. 2007;47:1809–1815
  76. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, et al. Experience of German red cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion. 2008;48:1558–1566
  77. Stramer SL. Current risks of transfusion-transmitted agents. Arch Pathol Lab Med. 2007;131:702–707
  78. Ramia S, Ramlawi F, Kanaan M, Klayme S, Naman R. Frequency and significance of antibodies against hepatitis B core (anti-HBc) antigen as the only serological marker for hepatitis B infection in Lebanese blood donors. Epidemiol Infect. 2005;133:695–699
  79. Katsoulidou A, Moschidis Z, Sypsa V, Chini M, Papatheodoridis GV, Tassopoulos NC, et al. Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load. Vox Sang. 2007;92:8–14
  80. Manzini P, Girotto M, Borsotti R, Giachino O, Guaschino R, Lanteri M, et al. Italian blood donors with anti-HBc and occult hepatitis B virus infection. Haematologica. 2007;92:1664–1670
  81. Makroo RN, Choudhury N, Jagannathan L, Parihar-Malhotra M, Raina V, Chaudhary RK, et al. Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus-1 & hepatitis B & C viruses in Indian blood donors. Indian J Med Res. 2008;127:140–147
  82. Comanor L, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang. 2006;91:1–12
  83. Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol. 2006;36:S33–S44
  84. Komiya Y, Katayama K, Yugi H, Mizui M, Matsukura H, Tomoguri T, et al. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion. 2008;48:286–294
  85. Hsia CC, Purcell RH, Farshid M, Lachenbruch PA, Yu MY. Quantification of hepatitis B virus genomes and infectivity in human serum samples. Transfusion. 2006;46:1829–1835
  86. Tsuge M, Hiraga N, Takaishi H, Noguchi C, Oga H, Imamura M, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology. 2005;42:1046–1054
  87. Tabuchi A, Tanaka J, Katayama K, Mizui M, Matsukura H, Yugi H, et al. Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. J Med Virol. 2008;80:2064–2068
  88. Inaba S, Ito A, Miyata Y, Ishii H, Kajimoto S, Tanaka M, et al. Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusion. Transfusion. 2006;46:2028–2029
  89. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion. 2007;47:1197–1205
  90. Wang JT, Lee CZ, Chen PJ, Wang TH, Chen DS. Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers. Transfusion. 2002;42:1592–1597
  91. Hoofnagle JH, Waggoner JG. Hepatitis A and B virus markers in immune serum globulin. Gastroenterology. 1980;78:259–263
  92. Stramer SL. Pooled hepatitis B virus DNA testing by nucleic acid amplification: implementation or not. Transfusion. 2005;45:1242–1246
  93. Soldan K, Barbara JAJ, Dow BC. Transfusion-transmitted hepatitis B virus infection in the UK: a small and moving target. Vox Sang. 2002;83:305–308
  94. Jongerius JM, van der Poel CL, van Leeuwen EF. A simple strategy to look back on posttransfusion hepatitis B in a multitransfused patient. Vox Sang. 1998;75:66–69
  95. Dreier J, Kroger M, Diekmann J, Gotting C, Kleesiek K. Low-level viraemia of hepatitis B virus in an anti-HBc- and anti-HBs-positive blood donor. Transfus Med. 2004;14:97–103
  96. Gerlich WH. Breakthrough of hepatitis B virus escape mutants after vaccination and virus reactivation. J Clin Virol. 2006;36:S18–S22
  97. Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol. 2008;48:1022–1025
  98. Wendel S, Levi JE, Biagini S, Candotti D, Allain J-P. A probable case of hepatitis B virus transfusion transmission revealed after a 13-month-long window period. Transfusion. 2008;48:1602–1608
  99. Chudy M, Schmidt M, Czudai V, Scheiblauer H, Nick S, Mosebach M, et al. Hepatitis B virus genotype G monoinfection and its transmission by blood components. Hepatology. 2006;44:99–107
  100. Gerlich WH, Wagner FF, Chudy M, Holm Harritshoj L, Lattermann A, Wienzek S, et al. HBsAg non-reactive HBV infection in blood donors: transmission and pathogenicity. J Med Virol. 2007;79:S32–S36
  101. Prince AM, Lee DH, Brotman B. Infectivity of blood from PCR-positive, HBsAg-negative, anti-HBs-positive cases of resolved hepatitis B infection. Transfusion. 2001;41:329–332
  102. Barcena R, Moraleda G, Moreno J, Martin MD, de Vicente E, Nuno J, et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol. 2006;12:2070–2074
  103. Dodson SF. Prevention of de novo hepatitis B infection after liver transplantation with allografts from hepatitis B core antibody positive donors. Clin Transplant. 2000;14:S20–S24
  104. Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBc positive donors. Gut. 2002;50:95–99
  105. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology. 2003;38:86–95
  106. Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, Günther S, et al. Serological pattern “anti-HBc alone”: report on a workshop. J Med Virol. 2000;62:450–455
  107. Allain JP, Hewitt PE, Tedder RS, Williamson L. Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion. Br J Haematol. 1999;107:186–195
  108. Mosley JW, Stevens CE, Aach RD, Hollinger FB, Mimms LT, Solomon LR, et al. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion. 1995;35:5–12
  109. Liu CJ, Lo SH, Kao JH, Tseng PT, Lai MY, Ni YH, et al. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol. 2006;44:39–46
  110. Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat. 2007;14:478–483
  111. Su FH, Chen JD, Cheng SH, Sung KY, Jeng JJ, Chu FY. Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18 years post-implementation of Taiwan’s national hepatitis B vaccination programme. J Viral Hepat. 2008;15:14–19
  112. Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis. 2007;5:79–84
  113. Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol. 1997;26:517–526
  114. Dickson RC, Wright RM, Bacchetta MD, Bodily SE, Caldwell SH, Driscoll CJ, et al. Quality of life of hepatitis B and C patients after liver transplantation. Clin Transplant. 1997;11:282–285
  115. Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation. 1998;65:494–499
  116. Kim KH, Ahn SH, Chung HY, Paik YH, Lee KS, Kim YS, et al. Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. J Gastroenterol Hepatol. 2004;19:847–853
  117. Llewelyn CA, Wells AW, Amin M, Casbard A, Johnson AJ, Ballard S, et al. The EASTR study: a new approach to determine the reasons for transfusion in epidemiological studies. Transfus Med. 2009;19:89–98
  118. Hollinger FB, Dodd RY. Hepatitis B virus traceback and lookback: factors to consider. Transfusion. 2009;49:176–184
  119. Allain JP, Belkhiri D, Vermeulen M, Crookes R, Cable R, Amiri A, et al. Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology. 2009;49:1868–1876
  120. Franklin IM, Dow BC, Jordan AD. Benefits of a blood donation archive repository: international survey of donor repository procedures and Scottish experiences. Transfusion. 2007;47:1172–1179
  121. Allain JP. Occult hepatitis B virus infection and transfusion. J Hepatol. 2006;44:618–619
  122. Prati D, Gerosa A, Porretti L. Occult HBV infection and blood transfusion. J Hepatol. 2006;44:818
  123. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood. 2009;113:3147–3153

☆ The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00391-2

doi: 10.1016/j.jhep.2009.05.020

Journal of Hepatology
Volume 51, Issue 4 , Pages 798-809 , October 2009

Article Tools

* Image Usage & Resolution